Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Uveal Melanoma × Melphalan × Clear all

Phase

Phase 3 3 Phase 1 3 Phase 2 1 Phase 1/2 1

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 40 Neoplasms, Plasma Cell 16 Lymphoma, Non-Hodgkin 13 Lymphoma 13 Leukemia 13 Leukemia, Myeloid, Acute 12 Myelodysplastic Syndromes 11 Hodgkin Disease 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Lymphoma, Mantle-Cell 7 Lymphoma, Follicular 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5 Lymphoma, Large B-Cell, Diffuse 4 Congenital Abnormalities 4 Neuroblastoma 3 Melanoma 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Myeloid, Accelerated Phase 3 Leukemia, Biphenotypic, Acute 3 Hematologic Neoplasms 3 Graft vs Host Disease 3 Burkitt Lymphoma 3 Smoldering Multiple Myeloma 2 Neoplasms 2 Myeloproliferative Disorders 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Leukemia, Myelomonocytic, Juvenile 2 Leukemia, Myeloid, Chronic-Phase 2

Interventions

Ipilimumab 5 Nivolumab 4 sargramostim 2 pembrolizumab 2 binimetinib 2 aldesleukin 2 Granulocyte-Macrophage Colony-Stimulating Factor 2 trametinib 1 tebentafusp 1 sotrastaurin 1 montanide ISA 51 1 incomplete Freund's adjuvant 1 glembatumumab vedotin 1 fludarabine 1 entrectinib 1 Tramadol 1 Thalidomide 1 Temozolomide 1 Solutions 1 Ruthenium-106 1 Radiotherapy 1 RNA, Messenger 1 Protein Kinase C 1 Melphalan 1 Magnetic Resonance Spectroscopy 1 Interleukin-2 1 Ibuprofen 1 Cyclophosphamide 1 Crizotinib 1 Carmustine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05893654 2025-09-15

MELCOM

Hospital das Clínicas de Ribeirão Preto

Phase 1/2 Enrolling by invitation

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡